Aspirin in Primary Prevention: Prudent Guideline-Based Approach Prof. (Dr.) J.P.S. Sawhney13 Jun 2025 11:44 AM ISTAspirin in Primary Prevention: Need for Delineating High CV-Risk, Low-Bleeding-Risk Profiles: Aspirin in primary prevention requires a nuanced,...
Aspirin Use in Male Smokers Aged 40-45 Years with Hypertension: Identifying the Ideal Candidates Dr. Milind Desai31 May 2025 10:53 AM ISTPremature ASCVD in IndiaIn India, over 50% of cardiovascular disease (CVD) deaths occur before 50 years, and 25% of myocardial infarction (MI) events...
Relevance of Pioglitazone in Indian T2DM Care Continuum Dr. Vijay Panikar27 May 2025 11:30 AM ISTIndia is experiencing a rising burden of type 2 diabetes (T2D), affecting 11.4% of adults. Hypertension (35.5%), generalized obesity (28.6%),...
Azmarda Outperforms Generic Sacubitril/Valsartan in HFrEF Management, says new study Dr. Garima Soni22 May 2025 11:30 AM ISTAhmedabad: Azmarda, an innovator brand of Sacubitril/Valsartan, demonstrated superior efficacy compared to generic Sacubitril/Valsartan in patients...
Re-visiting the Role of Pneumococcal Vaccination in Patients with Cardiovascular Diseases Dr. Sanjay Mittal14 May 2025 11:37 AM ISTCardiovascular diseases (CVD) account for 24.8% of all deaths in India, with an age-standardized death rate of 272 per 100,000-higher than the global...
Aspirin in Primary Prevention- When to Consider? Dr A B Chandorkar9 May 2025 11:16 AM ISTReframing Aspirin's Role in Primary Prevention: Evolving evidence has refined our understanding of aspirin's role in primary prevention. While earlier...
Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates Dr. Salil Vaidya28 April 2025 10:25 AM ISTCVD Risk in Women After 40: Cardiovascular disease (CVD) is the leading cause of death in individuals with type 2 diabetes (T2D) and hypertension. (1)...
Indian CV Risk Factors and Emerging Evidence for Aspirin in Primary Prevention- What's New? Dr. Jay Shah5 April 2025 11:32 AM ISTCardiovascular diseases (CVDs) remain the leading cause of mortality and disability in India, contributing to 31.8% of deaths. Noncommunicable...
Lipoprotein(a), ASCVD risk, and Aspirin- What is the Latest Evidence Saying? Dr. Roopali Khanna7 Feb 2025 12:21 PM ISTLipoprotein (a) [Lp(a)] is considered pro-atherosclerotic, pro-inflammatory, pro-thrombotic, and anti-fibrinolytic. Lipoprotein(a) levels >50 mg/dL...
Metoprolol in Coronary Artery Disease: Top 5 Evidence Insights Dr. S. N. Routray6 Feb 2025 11:41 AM ISTCoronary Artery Disease-A Concerning Epidemiology in India:India has the highest burden of acute coronary syndrome and ST-elevation myocardial...
Addressing Pneumococcal Disease in CKD Patients: A Call for Preventive Action Dr. Alan Almeida22 Jan 2025 11:49 AM ISTIn India, the prevalence of chronic kidney disease (CKD) has reached epidemic proportions, with population-based studies reporting a prevalence...
Primary Prevention with Aspirin: Lowering ASCVD Mortality in Adults with Elevated Lipoprotein(a) Dr Prakash Kumar19 Nov 2024 9:15 AM ISTQuick Takeaways:Elevated Lp(a) (>=50 mg/dL) significantly raises ASCVD risk, affecting around 25% of Indians.One-time Lp(a) screening in adulthood...
